Rank Ligand

(RANKL)
Inhibitor

-RANKL: a protein that acts as the primary signal to promote bone remo

Denosumab
(Prolia)

- Receptor Activator of
NF-B Ligand (RANKL)
Inhibitor
- It is a monoclonal antibody
that targets receptor
activator of nuclear factor
kappa -B ligand (RANKL) and
blocks osteoclast activation.
- Fully human monoclonal
antibody that targets
RANKL.
PK
- Administration: SC.

Uses
- For treatment of
postmenopausal
osteoporosis in
women at high risk
of fracture.
- Prevention of
skeletal-related
events in patients
with bone
metastases from
solid tumors .
Dose
- SC: 60 mg
administered as a
single subcutaneous
(in the upper arm,
the upper thigh, or
the abdomen)
injection once
every 6 months.
And all patients
should receive
calcium 1000 mg
daily and at least
400 IU vitamin D
daily.
- in bone
metastases from
solid tumors . 120
mg
subcutaneously
every 4 weeks
- No adjustment
for hepatic or
renal dysfunction
is
needed.

- Increas
infections
secondary
malignanc
hypocalce
(Patients
be taking
calcium/
and derm
reactions
and resp
tract infe
cataracts
constipa
rashes, j

C.I
- It shoul
reserved
intolerant
unrespons
other ost
therapies